Precision Medicine Market

Precision Medicine Market Research, 2032

Precision Medicine Market is expected to grow at a CAGR of 12.1% in the forecast period (2023-2032), with the market size valued at USD 39.66 billion in 2021 and projected to reach USD 138.6 billion by 2032.

Precision medicine, sometimes referred to as personalized medicine, is a healthcare strategy that customizes medical judgments, therapies, and treatments to specific patients by considering their distinctive genetic make-up, way of life, and environmental circumstances. It has become more well-known as a result of developments in genomics, genomic sequencing technology, and data analysis, which make it possible to identify genetic variations linked to diseases and provide tailored treatments. Precision medicine includes diagnostic tools, biomarker testing, and the integration of complicated patient data utilizing artificial intelligence and machine learning. It is mostly prominent in oncology but is moving into other medical fields. It is a dynamic and evolving industry since regulatory bodies are actively involved in forming the regulatory framework, yet issues with data privacy, standardization, and reimbursement still exist.

Market Highlights

Precision Medicine Market is expected to exhibit a CAGR of 12.1% during the forecast period

Precision Medicine Market is expected to reach USD 138.6 billion, growing at a CAGR of 12.1%. Advances in genomics and genetic sequencing technology are principally responsible for the sector of precision medicine's present remarkable expansion. These developments make it easier to find the genetic differences linked to diseases and to provide personalized treatments after that. Precision medicine is finding uses outside of oncology, increasing demand for diagnostic equipment and biomarker testing. The precision of treatment decisions is also being improved by the incorporation of substantial patient data and the use of artificial intelligence for data analysis. Precision medicine is positioned as a dynamic and promising strategy for improving patient care and outcomes thanks to regulatory authorities' support and the continual evolution of guidelines.

Precision Medicine Market Segmentation

Inhibitors Segment is expected to dominate in the forecast period

Based on the Type, the market is divided into Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral, and Others. Notably, the inhibitor medication category became the main player in this market in 2022. The demonstrated efficacy of inhibitor medications and the accessibility of a sizable number of commercially licensed pharmaceuticals falling under this category are two aspects that contribute to this leadership position. Additionally, a variety of important medical indications, including oncology and uncommon illnesses, are covered by inhibitor medications, which increases their market share and significance. The prominence of this section highlights its important contribution to the development of precision medicine.

Oncology Segment is expected to dominate in the forecast period

By Application, the Precision Medicine Market is typically segmented into Oncology, Rare diseases, Hematology, Infectious, and Others. Oncology has the biggest percentage of these due to a number of factors. There has been a marked rise in the number of oncology medications approved for personalized or precision treatment methods, which reflects the rising acceptance of the advantages of targeted cancer therapies. The prevalence of various cancer kinds has also been expanding globally, which has increased the need for precisely targeted therapies to address the many problems that cancer patients face around the world. As a result, oncology becomes a leader in the field of precision medicine, highlighting its crucial role in determining the direction of personalized healthcare.

Market Dynamics

Growth Drivers

Expansion of Genetic Testing and Related Procedures to Boost the Market

Only after a wide range of diagnostic tests has been used to evaluate the patient's genes, looking at unique variants, genetic mutations, and variances is a precision medicine regimen advised. Additionally, the therapeutic strategy comprises giving the patient a suitable therapy or medication regimen depending on the findings of genetic testing. The availability of tests for cancer screening, prenatal screening, and the accessibility of direct-to-consumer testing (DTC) are among the factors influencing the growth of genetic testing. Furthermore, genetic testing greatly speeds up the creation of companion diagnostics. Diagnostic techniques called companion diagnostics (CDx) are used to identify the patients most likely to benefit from a certain therapeutic intervention. These assessments enable the selection of individualized treatment alternatives, advancing precision medicine.

Increasing Demand for Cell and Gene Therapies will Hasten Market Expansion

Due to their potential to cure conditions for which there are now no viable medicines, cell and gene therapies have recently seen an increase in demand. These categories mostly cover rare genetic abnormalities, chronic diseases found in specialized domains like oncology, and other uncommon illnesses. Due to the increase in demand, pharmaceutical and biotechnology firms now have an alluring opportunity to invest in the creation and marketing of novel cell and gene therapies. Additionally, as cell and gene therapies have specific therapeutic benefits, they are referred to as customized medicine. For of the enormous advantages that cell and gene treatments provide, there is a growing market for them, which creates a big potential for precision medicine.

Restraints

High Cost of Therapy is Hurting the Market

Following a thorough examination of the patient's genetic profile using diagnostic genetic tests, precision medicine treatments are given. As a result, the overall costs of receiving treatment via precision medicine can be high. This might make it more difficult for people to get precision medicine if they are struggling financially or live in areas with inadequate healthcare infrastructure. However, it is anticipated that prices for customized medications will likely drop in the near future. This is for the reason that major players are working together to develop therapies at lower costs, and as regulatory agencies and healthcare providers are supporting precision medicine adoption and accessibility more and more.

Recent Developments

• A new Simvastatin Medication Insight report from 23andMe was released in July 2023. It is one of a number of 23andMe reports that examine how genetics may affect a person's response to particular drugs as well as their risk of experiencing side effects. The Simvastatin Medication Insight report examines how different people react to simvastatin, a statin medication used to decrease blood cholesterol that is also marketed under the names Zocor and Flolipid.
• Qiagen declared in June 2023 that the Danish National Genome Center had chosen the 'QCI Interpret' software for providing sequencing-based treatments for cancer patients. For evaluating cancer results derived from whole-genome sequencing data, the variant interpretation and reporting program have been selected. This advancement is a component of Denmark's personalized medicine plan, which includes providing WGS as the gold standard of care for pertinent patient populations.

Key Players:

• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Roche Holding AG
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• Bristol-Myers Squibb
• Novartis AG
• Amgen Inc.
• AstraZeneca PLC
• Gilead Sciences, Inc.
• Bio-Rad Laboratories, Inc.
• Foundation Medicine, Inc.
• Becton, Dickinson and Company (BD)
• Tempus, Inc.
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Precision Medicine Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. Due to significant expenditures made within the region, North America establishes its supremacy in the precision medicine market. Furthermore, the market's growth rate in North America is expected to be further accelerated by the increased adoption and use of precision medicine.

The Asia-Pacific area, meanwhile, is anticipated to rise significantly due to strong government measures. Furthermore, the adoption of big data in healthcare and the rise in cancer incidence are anticipated to accelerate market expansion in this area.

Precision Medicine Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Precision Medicine Market Scope and Segments:

Frequently Asked Questions (FAQ):